bioMerieux ( and NuGEN Technologies ( entered an agreement to cross-license intellectual property as well as a supply agreement for NuGEN’s exclusive WT-Ovation RNA Amplification System.

bioMerieux thus gained nonexclusive rights to specific NuGEN amplification technologies that will enable it to create and market in vitro diagnostic tests requiring amplification for expression analysis. In return, NuGEN will gain access to patented bioMerieux linear amplification technologies using chimeric primers, including extensive OEM rights for the research market.

The dual accord will enable bioMérieux to integrate NuGEN technologies for the development of a highly sensitive and automatable microarray-based assay for cancer with the objective to increase test easy-of-use and to reduce the time from sample acquisition to diagnosis.

Next articleUMMZ Periodical Cicada Page